Table 5. Clinical characteristics of kidney cancers; by variant alleles of CHEK2.
| Patients with truncating mutations (9) | p-value* | Patients with missense mutations (36) | p-value* | Patients with CHEK2 mutation (45) | p-value* | Patients with no mutations in CHEK2 (357) | |
|---|---|---|---|---|---|---|---|
| Age of diagnosis (yr) | |||||||
| Mean | 70.7 | 58.7 | 64.7 | 63.3 | |||
| Histological | |||||||
| features | |||||||
| Clarocellulare | |||||||
| GI | - | 3/30 (10) | 0.45 | 3/37 (8) | 0.24 | 55/321 (17) | |
| GII | 6/7 (86) | 0.05 | 14/30(47) | 0.81 | 20/37(54) | 0.25 | 137/321 (42) |
| GIII | 1/7 (14) | 0.74 | 11/30(37) | 0.36 | 12/37(33) | 0.62 | 87/321 (27) |
| GIV | - | 2/30 (6) | 0.78 | 2/37 (5) | 0.79 | 26/321 (8) | |
| Chromophobe | |||||||
| GI | - | - | - | 12/321 (4) | |||
| GII | - | - | - | 2/321 (1) | |||
| GIII | - | - | - | 2/321 (1) | |||
| Papillare | |||||||
| GI | 1/2 (50) | 0.87 | - | 1/8 (12) | 0.20 | 16/36 (44) | |
| GII | 1/2 (50) | 1.00 | 5/6 (84) | 0.28 | 6/8 (76) | 0.37 | 18/36 (50) |
| GIII | - | 1/6 (16) | 1/8 (12) | 2/36 (6) | |||
| Stage | |||||||
| Ta | 1/9 (11) | 0.19 | - | 1/45 (2) | 0.93 | 3/357 (1) | |
| T1 | 6/9 (67) | 0.85 | 25/36(70) | 0.99 | 31/45(69) | 0.93 | 248/357 (70) |
| T2 | 1/9 (11) | 0.77 | 4/36 (11) | 0.81 | 5/45 (11) | 0.74 | 30/357 (8) |
| T3 | 1/9 (11) | 0.81 | 7/36 (19) | 0.94 | 8/45 (18) | 0.89 | 71/357 (20) |
| T4 | - | - | - | - | 5/357 (1) |
* p-values are calculated with respect to carriers of noncarriers.
*GI-GIV–Fuhrman Grade.